Trial Profile
A Multicenter, Prospective, Open-label, Randomized Trial to Compare the Efficacy of Silodosin And Naftopidil In Patients With Benign Prostatic Enlargement (BPE) Complicated By Overactive Bladder (OAB).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Naftopidil (Primary) ; Silodosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Acronyms SNIPER
- 24 Oct 2016 New trial record
- 08 Sep 2016 Results of this trial, published in the Journal of Urology.